BioTuesdays

Author - Leonard Zehr

ContraVir Logo
Markets

Maxim starts ContraVir Pharma at buy

Maxim Group has initiated coverage of ContraVir Pharmaceuticals (NASDAQ:CTRV) with a “buy” rating and price target of $4, calling the company an emerging anti-viral leader with two clean shots on goal. The stock closed...

May 6, 2016
Titan Pharmaceuticals Logo
Developments

Titan Pharma’s Probuphine featured on CNBC

CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S. The feature...

May 4, 2016
TearLab
Markets

TearLab Q1 revenue climbs 25%

First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 25% to $6.8-million from $5.4-million a year ago. A net total of 257 TearLab Osmolarity Systems were added in the first quarter of 2016, of which 167 were...

May 4, 2016
Sarepta Therapeutics
Markets

Leerink downgrades Sarepta to under perform

Leerink has downgraded Sarepta Therapeutics (NASDAQ:SRPT) to “under perform” and slashed its price target to $5 from $13. The stock closed at $17.92 on Monday. Sarpeta has been a confounding stock for which to forecast...

May 3, 2016
Zomedica Pharmaceuticals
Markets

Zomedica Pharma listed on TSX Venture

The shares of Zomedica Pharmaceuticals (TSX-V:ZOM), a veterinary pharmaceutical company, have been listed on TSX Venture Exchange under the symbol, ZOM. “With our shares trading on TSX-V, Zomedica has a more-efficient...

May 2, 2016
Spectranetics
Markets

Canaccord ups Spectranetics price target to $23.50

Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday. “Our bullish conviction heading into the Q1 print was validated by the strong...

April 29, 2016
Profound Medical Logo
Developments

Profound Medical sells first TULSA-PRO device

Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral...

April 28, 2016
Strongbridge Biopharma Logo
Markets

HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made...

April 27, 2016